Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Tharimmune ( (THAR) ) is now available.
On January 26, 2026, Tharimmune announced it had been approved to operate as a Super Validator on the Canton Network, expanding its role in securing onchain financial transactions and earning Canton Coin rewards to strengthen its digital asset treasury. As part of this expanded role, the company committed to providing quarterly onchain analytics and governance research, hosting public webinars to engage ecosystem participants, and investing in Canton Network-based applications to drive institutional adoption across capital markets, positioning Tharimmune as a key publicly traded supporter of an emerging institutional blockchain infrastructure handling hundreds of thousands of daily transactions and trillions in monthly volume.
More about Tharimmune
Tharimmune, Inc. (NASDAQ: THAR) is a clinical-stage biotechnology company that also positions itself as a digital-asset-focused player, being the first publicly traded company to leverage Canton Coin to support the Canton Network and advance institutional blockchain adoption and the digitization of financial markets. Alongside its biotech research and development activities, the company pursues a differentiated digital asset treasury strategy centered on the Canton Network ecosystem.
Average Trading Volume: 1,428,685
Technical Sentiment Signal: Buy
Current Market Cap: $117M
For detailed information about THAR stock, go to TipRanks’ Stock Analysis page.